Efficacy and Safety of DaxibotulinumtoxinA (DAXI) for Injection for Treatment of Forehead Lines (Frontalis)

Completed · Phase 2

Conditions studied: Frown Lines

In brief

This is a phase 2a, multicenter, open-label, dose-escalation study to evaluate treatment of moderate or severe dynamic forehead lines (FHL) (frontalis) in conjunction with treatment of the glabellar complex.

Key facts

Study ID

NCT03786770

Run by

Revance Therapeutics, Inc.

People needed

61

Starts

2019-01-24

Expected to finish

2020-03-09

Last updated by the study team

2023-02-16

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Provide written informed consent consistent with International Conference on Harmonisation (ICH) Good Clinical Practice (GCP) guidelines and local laws, including authorization to release health information, signed prior to any study procedures being performed
• Be outpatient, male or female subjects, in good general health, 18-65 years of age
• Have a score of moderate (2) or severe (3) FHL during maximum contraction (eyebrow elevation) as assessed by the Investigator Global Assessment Forehead Wrinkle Severity (IGA-FHWS)
• Have a score of moderate (2) or severe (3) FHL during maximum contraction (eyebrow elevation) as assessed by the Patient Forehead Wrinkle Severity (PFHWS)
• Have a score of moderate (2) or severe (3) GL during maximum frown based on the Investigator Global Assessment Frown Wrinkle Severity (IGA-FWS) scale
• Have a score of moderate (2) or severe (3) on GL during maximum frown as assessed by the Patient Frown Wrinkle Severity (PFWS)
• Be willing to refrain from receiving facial fillers, laser treatments, use of any product that affects skin remodeling, or a product that may cause an active dermal response in the treatment areas (e.g., above the inferior orbital rim) from screening through the end of the study
• Able to understand the requirements of the study and be willing and able to follow all study procedures, attend all scheduled visits, and successfully complete the study.

You may not qualify if…

• Active skin disease, infections, or inflammation at the injection sites
• Plans to receive botulinum toxin type A anywhere in the face (other than study treatment) from screening through the end of the study
• History of clinically significant bleeding disorders
• Non-ablative laser or light treatments, microdermabrasion, or chemical peels (medium depth or deeper, for example trichloroacetic acid (TCA) or phenol) in the treatment areas within 3 months before enrollment through the end of the study
• Clinically significant laboratory values at screening that may interfere with a subject's ability to complete the study as determined by the investigator
• History of upper or lower lid blepharoplasty or brow lift
• Prior periorbital or forehead surgery

Where it is running

• Boca Raton site — Boca Raton, Florida, United States
• Coral Gables site — Coral Gables, Florida, United States
• Toronto, Ontario site — Toronto, Ontario, Canada
• Woodbridge, Ontario site — Woodbridge, Ontario, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.